Slow right prefrontal transcranial magnetic stimulation as a treatment for medication-resistant depression: a double-blind, placebo-controlled study

Depress Anxiety. 2004;19(1):59-62. doi: 10.1002/da.10144.

Abstract

Over the past decade, efforts have been made to assess the positive therapeutic effects of transcranial magnetic stimulation (TMS) by altering the excitability of the brain. We conducted a double-blind, placebo-controlled study to assess the efficacy of right prefrontal slow repetitive TMS in patients with treatment refractory major depression. This pilot study supports the therapeutic potential of rTMS in the low-frequency range of 1 Hz on right prefrontal cortex for the treatment of refractory major depression. Additional studies will be necessary to assess the efficacy of rTMS with different indices (frequency, intensity, and stimulation site) for major depression and other psychiatric diseases.

Publication types

  • Clinical Trial
  • Letter
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Aged
  • Antidepressive Agents / administration & dosage*
  • Depressive Disorder, Major / diagnosis
  • Depressive Disorder, Major / physiopathology
  • Depressive Disorder, Major / therapy*
  • Dominance, Cerebral / physiology
  • Double-Blind Method
  • Drug Resistance
  • Female
  • Humans
  • Male
  • Middle Aged
  • Outcome and Process Assessment, Health Care
  • Pilot Projects
  • Prefrontal Cortex / physiopathology*
  • Transcranial Magnetic Stimulation / therapeutic use*

Substances

  • Antidepressive Agents